The real-world effectiveness of Monjuvi (tafasitamab-cxix) in U.S. patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) was confirmed, along with factors associated with survival ...

"This is one of the first large, real-world, long-term studies to assess the efficacy of hydroxyurea outside of a controlled setting," said study author Paul George, MD, a pediatric hematology ...

Patients Patients with newly diagnosed standard-risk B-cell ALL, with or without Down’s syndrome, who did not have testicular leukemia or frank central nervous system (CNS) disease were eligible.